Download Sample
Loading...
| A07181 | Pages: 137 | Sep 2020 | 1262 Views | | |
| Author(s) : Sanjivan Gill , Onkar Sumant | Tables: 54 | Charts: 35 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the North America Liver Disease Treatment Market
Request Now !The North America liver disease treatment market accounted for $6,970 million in 2019, and is expected to reach $8,318 million by 2027, registering a CAGR of 5.2% from 2020 to 2027.
Vaccines segment is expected to witness a decline owing to the fact that vaccination programs were put on hold to concentrate on medical care for COVID-19.
Liver disease treatments are defined as any medical care provided to the patient suffering from liver diseases in form of vaccines and drugs. For instance, there are different types of drugs available to treat a wide range of liver related disorders such as antiviral drugs are utilized for treatment of hepatitis viral infection. Similarly, drugs such as corticosteroids are used in treatment of alcoholic hepatitis and immunosuppressants are administered to patients with a transplanted liver. In addition, other drugs used to cure liver related medical conditions include immunoglobulins, which are obtained from plasma of patients who have recovered from hepatitis B viral infection.
Get more information on this report : Request Sample Pages
Moreover, liver diseases also include use of vaccines to provide immunization against viral hepatitis. In addition, other major liver disease that require treatment include liver cancer. For instance, liver cancer is a highly fatal medical condition, hence requires treatment that includes use of targeted therapy and chemotherapy drugs.
Increase in alcohol consumption & use of illegal drugs and rise in prevalence of liver disease is the major factor that contributes toward the market growth. Moreover, factors such as surge in geriatric population and rise in government and non-government awareness programs also boost the North America liver disease treatment market growth.
However, stringent approval process related to drugs and resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C restrict the market growth. Conversely, presence of strong pipeline products offer lucrative opportunities for the North America liver disease treatment market.
COVID-19 pandemic has affected every business adversely. For instance, after COVID-19 was declared as a pandemic by the WHO, countries worldwide adopted nationwide lockdowns to observe social distancing as a measure to contain the spread. This led to disruption, limitation, challenges, and changes in each sector of every industry in North America. Similarly, the liver disease treatment market was also impacted by the pandemic. Moreover, every segment in the market had a different impact. For instance, vaccines suffered a negative impact as immunization programs were halted. In addition, immunosuppressants were also affected in a negative manner. This was attributable to the fact that liver transplants decreased during lockdown as these procedures are elective and can be postponed. Similarly, other treatment types such as corticosteroids had a moderate impact from lockdowns.
The North America liver disease treatment market is segmented on the basis of treatment type, disease type, and country to provide a detailed assessment of the market. By treatment type, the market is divided into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy. By disease type, it is divided into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others. By country, it is classified into the U.S., Canada, and Mexico.
Get more information on this report : Request Sample Pages
On the basis of treatment type, anti-viral drugs occupied major share of the North America liver disease treatment market size in 2019, and is expected to remain dominant throughout the forecast period. The growth of this segment is attributable to rise in incidences of hepatitis in North America, which requires use of anti-viral drugs. Furthermore, the vaccines segment is expected to acquire the fastest growth rate during the forecast period, owing to presence of government bodies and pharmaceutical companies, which work to ensure proper vaccine coverage in North America. In addition, surge in awareness related to importance of immunization against hepatitis is another major factor that drives growth of the vaccines segment.
By disease type, the hepatitis segment occupied a major share of the market in 2019, owing to widespread prevalence of the disease in North America. In addition, the cancer segment is expected to witness highest growth rate during the forecast period, owing to rise in R&D expenditures related to cancer treatment. Furthermore, rise in focus of key players on developing new liver cancer treatments is also expected to drive the North America liver disease treatment market.
Get more information on this report : Request Sample Pages
In 2019, the U.S. accounted for the major share of the North America liver disease treatment market size, and is expected to continue this trend, owing to surge in prevalence of hepatitis, presence of huge number of geriatric populations, and easy availability of liver disease treatments. Moreover, other factors such as surge in health expenditure also boosts growth of the liver disease treatment market in North America. Mexico is expected to exhibit fastest growth rate, owing to surge in awareness related to use of liver disease treatments. In addition, surge in awareness related to importance of immunization against hepatitis in the country also propels the North America liver disease treatment market growth.
The North America liver disease treatment market is highly competitive and prominent players in the market have adopted various strategies to garner maximum North America liver disease treatment market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Astellas Pharma Inc., Mylan, AbbVie Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Eli Lilly and Company, Dynavax Technologies, Pfizer Inc., Gilead Sciences, Inc., Bristol Myers Squibb, and Emergent BioSolutions (Cangene bioPharma).
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
By Treatment Type
By Disease Type
By Country
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.2.1.List of key players profiled in the report
1.3.Research methodology
1.3.1.Primary research
1.3.2.Secondary research
1.3.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key Findings
3.2.1.Top Winning Strategies
3.2.2.Top investment pockets
3.3.Key forces shaping North America liver disease treatment industry/market
3.4.Top player positioning, 2019
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in consumption of alcoholic beverages and use of illegal drugs
3.5.1.2.Surge in prevalence of liver diseases
3.5.1.3.Rise in geriatric population
3.5.1.4.Increase in government and non-government awareness programs
3.5.2.Restraints
3.5.2.1.Stringent regulatory approvals related to liver disease treatment drugs and vaccines
3.5.2.2.Resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C
3.5.3.Opportunity
3.5.3.1.Presence of strong pipeline products
3.5.4.Impact Analyses
3.6.COVID-19 Impact Analysis on North America Liver Disease Treatment Market
CHAPTER 4:NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Antiviral Drugs
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by country
4.3.Immunosuppressants
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by country
4.4.Vaccines
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by country
4.5.Immunoglobulins
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by country
4.6.Corticosteroids
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by country
4.7.Targeted Therapy
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by country
4.8.Chemotherapy
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by country
CHAPTER 5:NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Hepatitis
5.2.1.Market size and forecast, by country
5.3.Autoimmune Diseases
5.3.1.Market size and forecast, by country
5.4.Non-Alcoholic Fatty Liver Disease (NAFLD)
5.4.1.Market size and forecast, by country
5.5.Cancer
5.5.1.Market size and forecast, by country
5.6.Genetic Disorders
5.6.1.Market size and forecast, by country
5.7.Others
5.7.1.Market size and forecast, by country
CHAPTER 6:NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast
6.2.U.S.
6.2.1.Market share & forecast, by treatment type
6.2.2.Market share & forecast, by disease type
6.3.Canada
6.3.1.Market share & forecast, by treatment type
6.3.2.Market share & forecast, by disease type
6.4.Mexico
6.4.1.Market share & forecast, by treatment type
6.4.2.Market share & forecast, by disease type
CHAPTER 7:COMPANY PROFILES
7.1.ABBVIE INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.ASTELLAS PHARMA INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.BRISTOL-MYERS SQUIBB COMPANY
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.3.6.Key strategic moves and developments
7.4.DYNAVAX TECHNOLOGIES CORPORATION
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.ELI LILY AND COMPANY
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.GILEAD SCIENCES, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.MERCK & CO. INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.MYLAN N.V.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.PFIZER INC. (PHARMACIA CORPORATION)
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
7.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 02.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR ANTIVIRAL, BY COUNTRY 2019–2027($MILLION)
TABLE 03.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 04.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR VACCINES TYPE, BY COUNTRY 2019–2027 ($MILLION)
TABLE 05.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR IMMUNOGLOBULINS, BY COUNTRY 2019–2027 ($MILLION)
TABLE 06.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY 2019–2027 ($MILLION)
TABLE 07.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY 2019–2027 ($MILLION)
TABLE 08.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CHEMOTHERPAY, BY COUNTRY 2019–2027($MILLION)
TABLE 09.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2019-2027 ($MILLION)
TABLE 10.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY REGION 2019–2027($MILLION)
TABLE 11.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY REGION 2019–2027 ($MILLION)
TABLE 12.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE, BY REGION 2019–2027 ($MILLION)
TABLE 13.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR CANCER, BY REGION 2019–2027($MILLION)
TABLE 14.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR GENETIC DIOSRDERS, BY REGION 2019–2027 ($MILLION)
TABLE 15.NORTH AMERICA LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY REGION 2019–2027($MILLION)
TABLE 16.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 18.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 19.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 20.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 21.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 22.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2027 ($MILLION)
TABLE 23.ABBVIE: COMPANY SNAPSHOT
TABLE 24.ABBVIE: OPERATING SEGMENTS
TABLE 25.ABBVIE: PRODUCT PORTFOLIO
TABLE 26.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 27.ASTELLAS: COMPANY SNAPSHOT
TABLE 28.ASTELLAS: OPERATING SEGMENTS
TABLE 29.ASTELLAS: PRODUCT PORTFOLIO
TABLE 30.BMS: COMPANY SNAPSHOT
TABLE 31.BMS: PRODUCT PORTFOLIO
TABLE 32.BMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 33.DYNAVAX TECHNOLOGIES: COMPANY SNAPSHOT
TABLE 34.DYNAVAX TECHNOLOGIES: PRODUCT PORTFOLIO
TABLE 35.DYNAVAX TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 36.ELI LILLY: COMPANY SNAPSHOT
TABLE 37.LILLY: OPERATING SEGMENTS
TABLE 38.ELI LILLY: PRODUCT PORTFOLIO
TABLE 39.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 40.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
TABLE 41.EMERGENT SOLUTIONS: OPERATING SEGMENTS
TABLE 42.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
TABLE 43.GILEAD: COMPANY SNAPSHOT
TABLE 44.GILEAD: OERATING SEGMENT
TABLE 45.GILEAD: PRODUCT PORTFOLIO
TABLE 46.MERCK: COMPANY SNAPSHOT
TABLE 47.MERCK: OPERATING SEGMENTS
TABLE 48.MERCK: PRODUCT PORTFOLIO
TABLE 49.MYLAN: COMPANY SNAPSHOT
TABLE 50.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 51.MYLAN: PRODUCT PORTFOLIO
TABLE 52.PFIZER: COMPANY SNAPSHOT
TABLE 53.PFIZER: OERATING SEGMENT
TABLE 54.PFIZER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.NORTH AMERICA LIVER DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES (2017–2019)
FIGURE 03.TOP WINNING STRATEGIES:%AGE DISTRIBUTION, (2017–2019)
FIGURE 04.DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 05.TOP INVESTMENT POCKETS
FIGURE 06.LOW BARGAINING POWER OF SUPPLIER
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH INTENSITY OF RIVALRY
FIGURE 10.LOW THREAT OF NEW ENTRANT
FIGURE 11.TOP PLAYER POSITIONING, 2019
FIGURE 12.IMPACT ANALYSIS, NORTH AMERICA LIVER DISEASE TREATMENT MARKET
FIGURE 13.ABBVIE: NET SALES, 2017–2019 ($MILLION)
FIGURE 14.ABBVIE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 15.ABBVIE: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 16.ASTELLAS: NET SALES, 2017–2019 ($MILLION)
FIGURE 17.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 18.ASTELLAS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 21.DYNAVAX TECHNOLOGIES: NET SALES, 2017–2019 ($MILLION)
FIGURE 22.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 23.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 24.EMERGENT SOLUTIONS: NET SALES, 2017–2019 ($MILLION)
FIGURE 25.EMERGENT SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 26.EMERGENT SOLUTIONS: REVENUE SHARE, BY REGION, 2019(%)
FIGURE 27.GILEAD: NET SALES, 2017–2019 ($MILLION)
FIGURE 28.MERCK: NET SALES, 2017–2019 ($MILLION)
FIGURE 29.MERCK: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 30.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 33.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
According to CXOs of top companies in the market, surge in prevalence of various liver related conditions such as hepatitis and liver cancer, which require use of liver disease treatments boost growth of the market.
Furthermore, experts of key companies believe surge in geriatric population, which is more prone to liver diseases, rise in awareness toward early detection and treatment of liver diseases, and increase in government programs designed to spread awareness related to hepatitis prevention also fuel growth of the North America liver disease treatment market.
Moreover, on the basis of country, the U.S. acquired major share of the market, owing to rise in healthcare expenditure and easy availability of liver disease treatments. Similarly, Mexico is expected to exhibit fastest growth rate during the forecast period, owing to surge in awareness associated with use of liver disease treatments.
A. The total market value of North America liver disease treatment market is $6,969.82 million in 2019.
A. The forecast period for North America liver disease treatment market is 2020 to 2027
A. The market value of North America liver disease treatment market in 2019 is $5,852.49 million.
A. The base year is 2019 in North America liver disease treatment market
A. Top companies such as, Gilead Sciences, Inc., AbbVie Inc., Merck & Co. Inc., Eli Lily and Company, and Pfizer Inc held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. Antiviral drugs segment is the most influencing segment as these medications are used in the treatment of highly prevalent hepatitis viral infections.
A. The major factor that fuels the growth of the North America liver disease treatment market includes rise in prevalence of various liver related medical conditions which require the use of liver disease treatment products.
A. Mexico has the highest growth rate in the market with a CAGR of 6.8%. This is due to rise in healthcare expenditure in the region and surge in awareness related to importance of immunization against hepatitis.
A. Medical care given to a patient suffering from liver diseases is termed as liver disease treatment. Furthermore, the treatment includes use of various drugs for different types of liver conditions.
A. Liver disease treatment products include different kinds of drugs and vaccines. For instance, anti-viral drugs are used to treat hepatitis that cause liver inflammation.
Enterprise
License/PDF
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers